Biofrontera AG (BFRA)


-0.08 (-2.91%)
Symbol BFRA
Price $2.67
Beta 1.548
Volume Avg. 0.03M
Market Cap -
Shares () -
52 Week Range 1.5-7.54
1y Target Est -
DCF Unlevered BFRA DCF ->
DCF Levered BFRA LDCF ->
ROE -94.92% Strong Sell
ROA -24.16% Sell
Operating Margin -
Debt / Equity 335.53% Strong Buy
P/E -4.35 Strong Sell
P/B 4.05 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest BFRA news

Dr. Hermann Lbbert
Nasdaq Capital Market

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.